- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Zenas Bio rises after over $1M stock purchase by CEO | 1 | Seeking Alpha | ||
| Mi | Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 | 2 | GlobeNewswire (USA) | ||
| 16.01. | Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 06.01. | ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study | 2 | Zacks | ||
| ZENAS BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 06.01. | Zenas Biopharma: H.C. Wainwright bestätigt Kaufempfehlung nach positiven Studiendaten | 11 | Investing.com Deutsch | ||
| 06.01. | Why Zenas BioPharma's Selloff Was Structurally Inevitable | 8 | Benzinga.com | ||
| 06.01. | Zenas Biopharma stock maintains Buy rating at H.C. Wainwright after positive trial data | 4 | Investing.com | ||
| 06.01. | Jefferies lowers Zenas Biopharma stock price target to $48 on trial data | 3 | Investing.com | ||
| 05.01. | Zenas Biopharma stock rating downgraded by Morgan Stanley on trial results | 12 | Investing.com | ||
| 05.01. | Zenas BioPharma Stock Plummets 57% Despite Positive Phase 3 INDIGO Results | 1 | RTTNews | ||
| 05.01. | Zenas Bio Inflammation Drug Meets Phase 3 Goals, But Is It Enough to Compete With Amgen? | 10 | MedCity News | ||
| 05.01. | Zenas shares crash after top drug misses expectations in immune disease study | 7 | BioPharma Dive | ||
| 05.01. | Zenas BioPharma Touts Phase 3 Win, But Stock Crashes | 2 | Benzinga.com | ||
| 05.01. | Zenas' stock sinks in wake of autoimmune phase 3 data despite primary endpoint hit | 4 | FierceBiotech | ||
| 05.01. | Zenas crashes as late-stage trial data for lead asset disappoint | 5 | Seeking Alpha | ||
| 05.01. | Zenas: Phase 3 INDIGO Trial Of Obexelimab Meets Primary Endpoint | 6 | RTTNews | ||
| 05.01. | Zenas BioPharma's obexelimab shows 56% reduction in IgG4-RD flares | 2 | Investing.com | ||
| 05.01. | Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) | 256 | GlobeNewswire (Europe) | - Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare - - Obexelimab also met and demonstrated statistically... ► Artikel lesen | |
| 05.01. | Zenas BioPharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.12.25 | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) |
1 2 3 4 Weiter >>
71 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 325,15 | +0,06 % | Märkte am Morgen: "KI-Realitätscheck", Wolters Kluwer, AMD, Amgen, Walmart, Novo Nordisk | Die Stimmung an den Aktienmärkten ist derzeit sehr, sehr wechselhaft. Das war gestern deutlich zu spüren. Der DAX war bemerkenswert stark in den Handel gestartet, schloss allerdings leicht im Minus.... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 662,80 | -0,27 % | REGENERON PHARMACEUTICALS, INC. - 10-K, Annual Report | ||
| BIOMARIN PHARMACEUTICAL | 49,320 | +0,28 % | Assessing BioMarin Pharmaceutical: Insights From 5 Financial Analysts | ||
| ARROWHEAD PHARMACEUTICALS | 56,04 | +2,75 % | S&P Dow Jones Indices: Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 | NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:
S&P MidCap 400... ► Artikel lesen | |
| INSMED | 127,00 | 0,00 % | Insmed Incorporated: Insmed Provides Clinical and Business Update | -Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed Discontinues... ► Artikel lesen | |
| SWEDISH ORPHAN BIOVITRUM | 37,020 | +0,05 % | Swedish Orphan Biovitrum AB Profit Rises In Q4 | STOCKHOLM (dpa-AFX) - Swedish Orphan Biovitrum AB (SWOBY) announced earnings for its fourth quarter that Increases, from the same period last yearThe company's bottom line totaled SEK1.861 billion... ► Artikel lesen | |
| SCHOLAR ROCK | 39,000 | -3,47 % | AKTIONÄR-Tipp Scholar Rock mit Kurssprung - das ist der Grund | Die Aktie des Biotech-Unternehmens Scholar Rock konnte am Freitag einen satten Kurssprung von mehr als 20 Prozent hinlegen. Die Gesellschaft hat ihre Quartalszahlen vorgelegt und in diesem Rahmen positive... ► Artikel lesen | |
| PROQR THERAPEUTICS | 1,304 | +2,44 % | ProQR Therapeutics N.V.: ProQR Announces Third Quarter 2025 Operating and Financial Results | Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability... ► Artikel lesen | |
| CRINETICS PHARMACEUTICALS | 38,400 | 0,00 % | XFRA 6Z4: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,960 | +0,14 % | MEDICAL BioHealth Fonds: Eli Lilly kauft Ventyx Biosciences | Gräfelfing (www.fondscheck.de) - Anbei eine aktuelle Pressemitteilung der Medical Strategy GmbH:Zum Kauf von Ventyx Biosciences durch Eli Lilly ein Statement von Mario Linimeier, Geschäftsführer der... ► Artikel lesen | |
| THERATECHNOLOGIES | 2,780 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 06.10.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 06.10.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 06.10.2025.ISIN NameAT0000A3PGY9 UBM... ► Artikel lesen | |
| ENSYSCE BIOSCIENCES | 0,467 | +1,74 % | Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain | ~ Engineered to Deliver Potent Pain Relief with Built-In Abuse Protection ~ SAN DIEGO, CA / ACCESS Newswire / January 28, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company")... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 43,090 | +1,20 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Provides Corporate Update | - ARCALYST- (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth -- ARCALYST 2026 net product revenue expected to be $900 - $920 million --... ► Artikel lesen | |
| TEVOGEN BIO | 0,224 | -3,03 % | Tevogen Bio Inc: Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders | WARREN, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that its Board of Directors has expressed its intention to evaluate... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Das Unternehmen ZENAS BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +3,71 % bei einem Aktienkurs von 21,790 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENAS BIOPHARMA INC finden Sie auf Wallstreet Online.